Nora Pharma

What Nora Pharma does

Nora Pharma is a Canadian pharmaceutical company specializing in the nationwide distribution of generic prescription drugs, over-the-counter products, and biosimilars. Founded in 2017 by Malek Chamoun and headquartered in a 15,000 square foot Health Canada-certified facility in Varennes, Quebec, the company distributes directly to pharmacies and pharmacy chains across Canada through a national sales team with territory managers covering all provinces. Since October 2022, Nora Pharma has operated as a wholly owned subsidiary of Sunshine Biopharma Inc. (NASDAQ: SBFM), acquired for approximately $30 million CAD, with Catherine Péloquin succeeding Malek Chamoun as President in April 2025.

The company's product portfolio comprised 76 generic prescription drugs on the Canadian market as of Q3 2025, spanning therapeutic areas including oncology support (Anastrozole, pegfilgrastim biosimilar NIOPEG), anticoagulation (Rivaroxaban, Apixaban), cardiovascular health (Pravastatin), gastrointestinal disorders (Domperidone), and pain management (Tramadol/Acetaminophen), with 12 additional drugs in the pipeline for 2026 including Everolimus. The underlying technology is conventional pharmaceutical distribution built on Health Canada regulatory approvals and exclusive commercial rights agreements (notably a partnership with an established biopharmaceutical partner for biosimilars); Nora Pharma does not conduct primary manufacturing and holds no disclosed patents. The company owns the Priva brand acquired from Pharmapar.

The business model is direct pharmacy distribution: Nora Pharma sells generic and specialty products to Canadian pharmacy buyers at pricing determined through pharmacy benefit plans and provincial drug formularies, with revenue from one-time product sales rather than recurring subscriptions. Reported Q3 2025 revenue grew 11.6% to $9.42 million with a 24% reduction in net loss, supported by sequential product launches and a tripling of the business since the 2022 acquisition baseline of $10.7 million in revenue. The go-to-market is sales-led through the national sales organization, with Lea Solutions operating as a service arm and no digital or API-driven channels.

Name

Nora Pharma

Legal name

NORA PHARMA INC.

Website

https://norapharma.ca

Company type

Private

Founded year

2017

Operating status

Operating

Headcount range

11–50 employees

Short description

Nora Pharma is a Canadian pharmaceutical company that distributes generic medications, over-the-counter products, and biosimilars directly to pharmacies across Canada, operating as a wholly owned subsidiary of Sunshine Biopharma.

Ownership category

akta.pro rank

Product category

Generic Pharmaceuticals

NAICS

Pharmaceutical Preparation Manufacturing (325412), Biological Product (except Diagnostic) Manufacturing (325414), Drugs and Druggists' Sundries Merchant Wholesalers (424210)

SIC

Pharmaceutical Preparations (2834), Biological Products, (No Disgnostic Substances) (2836), Wholesale-Drugs, Proprietaries & Druggists' Sundries (5122)

akta.pro primary industry

Primary Care & General Medicine Pharmaceuticals (HLAIAAAA)

akta.pro secondary industry

Cardiometabolic Pharmaceuticals (Cardiovascular/Diabetes/Obesity) (HLAIAAAE)

Keywords

• Generic prescription drugs
• Pharmaceutical distribution
• Biosimilar products
• Over-the-counter medications
• Generic drug manufacturing

Headquarters

HQ city

Varennes

HQ country

Canada

HQ region

North America

Offices2 records

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Supply Chain, Personnel, Operations, Marketing or Sales, Others

Revenue model

1. Generic Prescription Drugs: Sale of generic prescription medications to pharmacies across Canada. The company distributes through its wholly owned Canadian subsidiary Nora Pharma Inc. Revenue reported at $9.42 million for Q3 2025 with 11.6% revenue growth.
2. Biosimilars: Commercialization of biosimilar products including NIOPEG, a pegylated filgrastim biosimilar. Part of the company's specialty product portfolio.
3. Over-the-Counter Products: Distribution of OTC pharmaceutical products as part of the broader product portfolio.

Go-to-market motion2 records

Distribution channels1 record

Marketing channels1 record

Core offering

Nora Pharma is a Canadian pharmaceutical company that develops, commercializes, and distributes generic prescription drugs, biosimilars, and over-the-counter products to pharmacies across Canada. Operating as a wholly owned subsidiary of Sunshine Biopharma, it markets a portfolio of 76 Health Canada-approved generic medications spanning cardiovascular, anticoagulant, oncology, and gastrointestinal therapeutic areas.

Product overview

Nora Pharma is a Canadian pharmaceutical company specializing in the nationwide distribution of generic medications and specialty drugs. The company operates as a wholly owned subsidiary of Sunshine Biopharma and positions itself as a partner to healthcare professionals and pharmacies. Nora Pharma's portfolio includes generic prescription drugs across therapeutic areas (cardiovascular/cholesterol, anticoagulants, oncology, gastrointestinal), biosimilars (NIOPEG®), and over-the-counter products. The company has 76 generic drugs on the Canadian market with 12 additional drugs in the pipeline expected to launch in 2026.

Differentiator

Problem solved

Functional benefit

Brands

• Priva: Generic drug brand acquired from Pharmapar, brought under full Quebec control through Nora Pharma's acquisition of Pharmapar assets.

Products and services

• NIOPEG® A biosimilar of NEULASTA® (pegfilgrastim), a long-acting pegylated form of filgrastim (r-HuG-CSF) indicated to decrease infection incidence in patients with non-myeloid malignancies receiving myelosuppressive anti-neoplastic drugs. Available in a pre-filled syringe of 6 mg/0.6 mL. Aimed at oncology patients and healthcare providers.
• Pravastatin Generic cholesterol-lowering medication used to address cardiovascular health, distributed to pharmacies across Canada.
• Domperidone Generic medication for nausea and gastrointestinal motility disorders, approved by Health Canada for commercialization in Canada.
• Anastrozole Generic equivalent of Arimidex® (1mg tablets) for the treatment of breast cancer, approved by Health Canada.
• Rivaroxaban Generic anticoagulant tablet available in four dosage strengths (2.5mg, 10mg, 15mg, 20mg); Nora Pharma's second generic anticoagulant after Apixaban.
• Apixaban Generic anticoagulant that has been on the Canadian market for over three years through Nora Pharma.
• Tramadol/Acetaminophen Generic pain medication with educational resources available for healthcare professionals.
• Over-the-Counter Products Portfolio of OTC pharmaceutical products distributed to pharmacy partners across Canada as part of the broader product offering.

Quantifiable outcome

• 11.6% revenue growth to $9.42 million in Q3 2025
• +3 more outcomes

Named customers1 record

Segments2 records

Ideal customer profiles2 records

Technology focussed No

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature5 records

Partnerships

Three partnerships are on record, tiered core and major.

• Lea SolutionscoreOthers · 1 March 2022Lea Solutions is the service arm of Nora Pharma that commercializes under its own name. It continues to operate without changes following the Sunshine Biopharma acquisition.
• PharmaparmajorStrategic or Co-development Partner · 1 March 2022Nora Pharma acquired assets of Pharmapar, a Quebec-based company distributing generic drugs for over 20 years. The acquisition added 15,000 square feet of infrastructure including a state-of-the-art warehouse and brought the Priva brand under Quebec control. Pharmapar customers gained access to Nora Pharma's product portfolio of over 120 products.
• Unnamed Biopharmaceutical PartnercoreStrategic or Co-development Partner · 24 August 2021Exclusive agreement with a biopharmaceutical partner with 40 years of industry experience and highest quality standards recognized by regulatory authorities worldwide. The partnership was for acquiring commercial rights to a biosimilar drug (later launched as NIOPEG). The agreement signaled Nora Pharma's ambition to become a key player in the Canadian pharmaceutical landscape.

Scale indicators8 records

Recent moves6 records

Expansion highlights5 records

Market position

Competitive moat4 records

Key risks6 records

Key highlights7 records

Customer concentration

• Xx.com/norapharma
• YouTubeyoutube.com/channel/norapharma
• LinkedInlinkedin.com/company/nora-pharma
• Facebookfacebook.com/norapharma.ca

Revenue estimate

Valuation estimate

Number of profiles

Profiles4 records

Subsidiaries1 record

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Nora Pharma